News and Events

Held June 13-16 at the Swedish Exhibition & Congress Centre, the 59th ESHG hybrid summit gathered roughly 7,000 genetic specialists, clinicians, and industry stakeholders from more than 90 nations.

Europe's top human genetics event convenes cross-disciplinary experts to discuss AI-driven variant interpretation, population-wide rare disease screening, multi-omics integration, liquid biopsy, and precision oncology, centering on translating genomic innovations into clinical diagnostic applications.

HaploX Booth Draws Strong Global Interest

As a leading Chinese enterprise in precision medicine, HaploX showcased its proprietary core technologies and full product portfolio at ESHG 2026.

HaploX has built a comprehensive product pipeline covering end-to-end oncology management, from early cancer screening and targeted and immunotherapy companion diagnostics, to chemotherapy medication guidance and longitudinal recurrence monitoring.

Flagship offerings include:

• StarPanel - comprehensive genomic profiling via high-throughput sequencing
• CorePanel - dynamic monitoring for targeted therapy and chemotherapy biomarkers
• MRD Assays - individualized minimal residual disease surveillance
• WESPlus - clinical-grade whole-exome sequencing and hereditary cancer panels

Together, these products address clinical demands spanning companion diagnostics to prognostic management.

On the regulatory front, multiple core assay kits and supporting bioinformatics software have obtained CE-IVD certification, while the human EGFR/ALK combined gene mutation detection kit holds NMPA Class III medical device registration, granting market access in both the EU and China.

The proprietary GeneBrain(TM) cancer genomics insight system, paired with a cloud-based bioinformatics platform, delivers a fully digital end-to-end NGS analytical solution, reflecting HaploX's integration of Biotechnology (BT) and Information Technology (IT).

HaploX Featured Presentation Captures Wide Academic Attention

On June 13 and 14, Fengxiang Bi, Global Product Marketing Manager at HaploX, delivered a keynote presentation titled "Multi-omics & Gene Testing: Partner with HaploX for Genomic Excellence."

The talk positioned HaploX as a full-chain precision medicine partner, capable of delivering complete solutions spanning basic research, pharmaceutical development, and end-to-end oncology management, from multi-omics research services to clinical-grade IVD products.

Backed by the proprietary LIUDUS integrated BT+IT+AI platform and a global service network covering more than 50 countries across five continents, HaploX provides one-stop support from sample processing to report interpretation for over 300 top-tier hospitals and more than 1,000 research institutions worldwide.

Its laboratory facilities hold internationally recognized accreditations including CAP, CLIA, and EMQN, alongside CE-IVD-certified core assay kits and analytical software.

The presentation received an enthusiastic response, with numerous international attendees engaging in follow-up academic discussions and partnership conversations.

Outlook

Having consecutively participated in ESHG conferences since Berlin 2024, HaploX has earned recognition and trust from global peers through cutting-edge technology and open collaboration.

This year's attendance not only exhibited HaploX's latest advancements in multi-omics services, AI and big data, intelligent analytical workstations, CE-IVD-certified IVD kits, and clinical product pipelines, but also expanded the company's global collaboration footprint via in-depth dialogues with world-leading scholars.

Guided by its mission to become a globally leading life sciences firm, HaploX will continue to deepen its focus on oncology liquid biopsy and genomic big data.

Empowering multi-omics big data with artificial intelligence, the company will keep advancing the global reach of China's precision medical technologies, and looks forward to connecting with partners at more international academic events ahead.